Clinical Trial Update: A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) [Phase 3]

View source ↗

Summary

Phase 3 trial of VB-111 plus paclitaxel versus paclitaxel alone in recurrent platinum-resistant ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• VB-111

Snippet

Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics | Conditions: Recurrent Platinum Resistant Ovarian Cancer | Phase 3 | Status: COMPLETED